December 10, 2009 (FinancialWire) — BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has named Charles A. Sanders to the company’s board of directors. Sanders is retired from Glaxo, Inc., where he served as chief executive officer from 1989 through 1994 and chairman of the board from 1992 through 1995.

Before joining Glaxo, Sanders spent eight years with Squibb., where he held posts including the position of vice chairman. He also served as chief executive officer of the Science and Technology Group and chairman of the Science and Technology Committee of the board.

Previously Sanders was General director of Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. A native of Dallas, he is a graduate of Southwestern Medical College of the University of Texas.

Alabama-based BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals designed to block enzymes involved in infectious diseases, cancer and inflammatory diseases.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279). Recently issued reports and/or recorded webcasts include Aria International Holdings, Inc. (OTCBB: ARAH), Continental Materials Corp. (AMEX: CUO), Darling International, Inc. (NYSE: DAR), Document Security Systems, Inc. (AMEX: DMC), and Juhl Wind, Inc. (OTCBB: JUHL).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.